Parallel import is based on the principle of free movement of goods within the EU-EEA (The European Economic Area).
Parallel importation of pharmaceuticals is original medicine being imported from an lowerpriced EU-EEA country, and then sold in another EU-EEA country with a higher price level. The medicine is sold on the same conditions as the original manufacturer’s normal packaging. The medicine is being bought from approved wholesalers, and there is no difference between parallel imported medicine and the original medicine.
All imported pharmaceuticals have to be approved by the local medical authority - or the EMA (European Medicines Agency)
In 2015 about 23% of all pharmaceuticals distributed through Danish pharmacists are parallel imported and the figures for Norway and Sweden are about 10%. In Denmark this means parallel imported pharmaceuticals save the Danish consumers more than DKK 500 million every year.